Effects of intravenous lidocaine on perioperative pain management and postoperative recovery of tibial fractures

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064960

Enrollment

Unknown

Registered

2022-10-24

Start date

2022-06-23

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tibia fracture

Interventions

Group 1:Lidocaine is given intravenously

Group 2:0.9% NaCl is given intravenously

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age > 18 years, ASA I-III grade patients with elective tibia fracture surgery.

Exclusion criteria

Exclusion criteria: Hypersensitivity to lidocaine, pregnancy status, liver disease (defined as serum total bilirubin >= 2 mg/dl), renal impairment (defined as glomerular filtration rate <= 60 ml/min), cardiac arrhythmias, epilepsy, intellectual disability and Preoperative chronic medication of strong opioids (eg, morphine or transdermal fentanyl).

Design outcomes

Primary

Measure	Time frame
Opioid consumption 72 hours postoperatively;	—

Secondary

Measure	Time frame
Events with a pain score greater than 3 at 72 hours postoperatively;Time to first bowel movement;	—

Countries

China

Contacts

Public ContactLi Shuang

Guang'an People's Hospital

354192646@qq.com+86 15982680372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026